Health
FDA grants rare disease designations to investigational brain tumor drug – News-Medical.Net
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahom…
Reviewed by Emily Henderson, B.Sc.Sep 2 2020
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
DIPG is a fast-growing pediatric cancer that starts in the brain stem. It is one of several sub-categories of malignant gliomas,…
-
Business21 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business20 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News17 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business17 hours ago1 ASX dividend stock down 43% I’d buy right now